Kraig Biocraft Laboratories, Inc. (KBLB) — SEC Filings
Kraig Biocraft Laboratories, Inc. (KBLB) — 14 SEC filings. Latest: EFFECT (Apr 29, 2026). Includes 6 10-Q, 3 S-1/A, 2 10-K.
View Kraig Biocraft Laboratories, Inc. on SEC EDGAR
Overview
Kraig Biocraft Laboratories, Inc. (KBLB) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 12, 2025: Kraig Biocraft Laboratories, Inc. reported a net loss of $2,835,732 for the nine months ended September 30, 2025, an increase from the $2,547,264 net loss in the same period of 2024. The company generated no revenue in either period. Total operating expenses rose to $2,652,125 for the nine months en
Sentiment Summary
Across 14 filings, the sentiment breakdown is: 1 bearish, 12 neutral, 1 mixed. The dominant filing sentiment for Kraig Biocraft Laboratories, Inc. is neutral.
Filing Type Overview
Kraig Biocraft Laboratories, Inc. (KBLB) has filed 1 EFFECT, 6 10-Q, 2 10-K, 3 S-1/A, 1 S-1, 1 8-K with the SEC between Apr 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (14)
Risk Profile
Risk Assessment: Of KBLB's 13 recent filings, 2 were flagged as high-risk, 8 as medium-risk, and 3 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | $(2,835,732) |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $1,565,692 |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- Kim Thompson
- Louis Taubman
Industry Context
The biotechnology and advanced materials sector is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like Kraig Biocraft Laboratories are attempting to disrupt traditional material markets with novel solutions, such as spider silk, but face intense competition from established players and the need to prove commercial viability and scalability.
Top Tags
financials (5) · 10-Q (4) · quarterly-report (3) · sec-filing (3) · Biotechnology (2) · Spider Silk (2) · Equity Financing (2) · 10-K (2) · registration (2) · Kraig Biocraft Laboratories (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Revenue | $0 | No revenue generated for the nine months ended September 30, 2025, or 2024. |
| Net Loss | $(2,835,732) | Increased from $(2,547,264) in 2024 for the nine months ended September 30. |
| Cash and Cash Equivalents | $1,565,692 | Increased from $673,264 at December 31, 2024, primarily due to equity financing. |
| General and Administrative Expenses | $1,852,841 | Increased from $1,467,411 in 2024 for the nine months ended September 30. |
| Proceeds from Standby Equity Purchase Agreement | $1,925,702 | Key financing activity for the nine months ended September 30, 2025. |
| Accumulated Deficit | $(55,921,451) | Grew from $(53,085,719) at December 31, 2024, reflecting ongoing losses. |
| Accounts payable and accrued expenses - related party | $8,004,099 | Significant related party liability as of September 30, 2025. |
| Class A Common Stock Outstanding | 1,076,244,777 | Increased from 1,038,374,219 shares at December 31, 2024, indicating dilution. |
| Net Loss (Q2 2025) | $(726,133) | 54.8% reduction from Q2 2024, driven by cost controls. |
| Net Loss (YTD Q2 2025) | $(1,326,166) | 37.3% reduction from YTD Q2 2024, showing improved efficiency. |
| Related Party Liabilities | $9,478,904 | Total of Note payable, Royalty agreement payable, and Accounts payable - related party, as of June 30, 2025, highlighting financial dependence. |
| SEC File Number | 333-284773 | Identifies this specific registration statement |
| Filing Date | 20250214 | Date the amendment was submitted to the SEC |
| Reporting Period End Date | 2024-09-30 | Latest interim financial data available in the filing. |
| Fiscal Year End Date | 2023-12-31 | Previous full fiscal year financial data. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Kraig Biocraft Laboratories, Inc. (KBLB)?
Kraig Biocraft Laboratories, Inc. has 14 recent SEC filings from Apr 2024 to Apr 2026, including 6 10-Q, 3 S-1/A, 2 10-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of KBLB filings?
Across 14 filings, the sentiment breakdown is: 1 bearish, 12 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Kraig Biocraft Laboratories, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Kraig Biocraft Laboratories, Inc. (KBLB) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Kraig Biocraft Laboratories, Inc.?
Key financial highlights from Kraig Biocraft Laboratories, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for KBLB?
The investment thesis for KBLB includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Kraig Biocraft Laboratories, Inc.?
Key executives identified across Kraig Biocraft Laboratories, Inc.'s filings include Kim Thompson, Louis Taubman.
What are the main risk factors for Kraig Biocraft Laboratories, Inc. stock?
Of KBLB's 13 assessed filings, 2 were flagged high-risk, 8 medium-risk, and 3 low-risk.
What are recent predictions and forward guidance from Kraig Biocraft Laboratories, Inc.?
Forward guidance and predictions for Kraig Biocraft Laboratories, Inc. are extracted from SEC filings as they are enriched.